Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
- Arexvy Already January GP Rep Promotion Champion, Tarlige Tops HP Ranking
March 21, 2024
- SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
March 21, 2024
- JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
March 21, 2024
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
- Canaglu OD Tablet Version Approved in Japan
March 19, 2024
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
- Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
- Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
- Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
- Ono, Sibylla Strike Neuroscience Drug Discovery Pact
March 15, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Tecentriq Filed for Alveolar Soft Part Sarcoma in Japan: Chugai
March 15, 2024
- High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
- Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…